The Mental Health Clinician最新文献

{"title":"Pharmacists in clozapine clinics improving physical health monitoring.","authors":"Greg Spann,&nbsp;Lewis Austin,&nbsp;Edward King","doi":"10.9740/mhc.2022.06.193","DOIUrl":"https://doi.org/10.9740/mhc.2022.06.193","url":null,"abstract":"<p><strong>Introduction: </strong>People living with schizophrenia have a higher rate of comorbid physical health diseases and compared with the general population die earlier due to these diseases. A pharmacist working in an outpatient mental health clinic setting could assist with the management of physical health disease for this population. The aim of this study was to investigate whether having a pharmacist in a community clozapine clinic would improve adherence to physical health monitoring and whether this would have a positive effect on these physical health outcomes.</p><p><strong>Methods: </strong>This retrospective observational study compared patient data from 2 clozapine clinics; one where a pharmacist engaged in medication reviews and management of medication side effects, and another that did not have a pharmacist. The rates of physical health monitoring and the changes from baseline of physical health outcomes (weight, BMI, BP, HbA1c, and lipids) were compared after the first pharmacist intervention (medication review).</p><p><strong>Results: </strong>The pharmacist clinic had statistically higher rates of metabolic and ECG monitoring (glucose 48% vs 11%, <i>P</i> < .001; lipids 61% vs 7.1%, <i>P</i> < .001; ECG 15% vs 0%, <i>P</i> = .001). Positive trends in weight were identified in the pharmacist-group, although this failed to reach statistical significance.</p><p><strong>Discussion: </strong>This study shows that pharmacists providing regular medication reviews improves physical health monitoring for patients receiving clozapine.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 3","pages":"193-198"},"PeriodicalIF":0.0,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/88/i2168-9709-12-3-193.PMC9190272.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40572087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying olanzapine induced liver injury in the setting of acute hepatitis C: A case report.","authors":"Andrea Brelje,&nbsp;Bailey Fay,&nbsp;Scott Mariouw,&nbsp;Amy VandenBerg","doi":"10.9740/mhc.2022.06.210","DOIUrl":"https://doi.org/10.9740/mhc.2022.06.210","url":null,"abstract":"<p><p>Olanzapine is linked to asymptomatic, transient elevations of liver aminotransferases but is historically thought to rarely cause significant hepatotoxicity. Underlying liver disease is a risk factor for drug-induced liver injury and may complicate the differential diagnosis of acute transaminitis in patients taking medications associated with hepatotoxicity. Ms L presented with 2 months of new psychotic symptoms resulting in hospitalizations. Although psychosis previously improved with haloperidol, she reported symptoms concerning for akathisia. Restlessness improved and psychotic symptoms resolved after initiation of olanzapine. Concurrently, her alanine aminotransferase (ALT) was elevated, prompting further workup and new diagnosis of acute hepatitis C. Over the course of hospitalization, her ALT increased exponentially. Initially attributed solely to acute hepatitis C infection, ALT rapidly decreased after holding olanzapine, implying it was contributing to her liver injury. Subsequently, given her prior response, haloperidol was retrialed with close monitoring for adverse effects. Her subjective restlessness was treated with additional agents, and she was then transitioned to monthly haloperidol decanoate injections to further assist her adherence. Prior to discharge, she had resolution of psychosis and transaminitis. Olanzapine may contribute to hepatotoxicity with concurrent viral hepatitis, and clarity can be obtained by a trial of stopping the suspected medication. Furthermore, olanzapine, when combined with underlying liver disease, may have an additive effect on liver injury, resulting in accelerated elevations in liver aminotransferases.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 3","pages":"210-213"},"PeriodicalIF":0.0,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/46/i2168-9709-12-3-210.PMC9190265.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40572089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lithium toxicity following Roux-en-Y gastric bypass: Mini review and illustrative case.","authors":"Shahana Ayub,&nbsp;Sundas Saboor,&nbsp;Sadia Usmani,&nbsp;Sana Javed,&nbsp;Gauvain Kankeu Tonpouwo,&nbsp;Saeed Ahmed","doi":"10.9740/mhc.2022.06.214","DOIUrl":"https://doi.org/10.9740/mhc.2022.06.214","url":null,"abstract":"<p><p>Lithium is among the mainstays of treatment for bipolar disorder. Bariatric surgery can considerably change the oral bioavailability of drugs, particularly lithium. In this review, a 36-year-old male patient is described, who presented with lithium toxicity, including neurologic and gastric symptoms after undergoing Roux-en-Y gastric bypass. The mechanism of lithium toxicity is discussed; recommendations for clinicians regarding lithium use in postsurgical patients are provided; and previous case reports of lithium toxicity post-gastric bypass surgery are analyzed. Awareness and education of lithium absorption changes postbariatric surgery is essential for optimal patient care. Close clinical and drug concentration level monitoring is warranted.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 3","pages":"214-218"},"PeriodicalIF":0.0,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/bb/i2168-9709-12-3-214.PMC9190271.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40572086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of noncontrolled medication misuse patterns.","authors":"Amelia Slane,&nbsp;Sophie Robert,&nbsp;Christine Rarrick,&nbsp;Erin Weeda","doi":"10.9740/mhc.2022.06.199","DOIUrl":"https://doi.org/10.9740/mhc.2022.06.199","url":null,"abstract":"<p><strong>Introduction: </strong>The abuse potential of opioids and other controlled substances is well-known; however, reports of noncontrolled prescription medication (NCPM) misuse deserves further attention. Whereas several studies investigate patterns, motivations, and biochemical mechanisms underlying the misuse potential of NCPM, the clinical significance of NCPM misuse is not well-understood. The primary objectives of this project were to identify prescriber perceptions of NCPM misuse and evaluate patient reported patterns of misuse through survey responses.</p><p><strong>Methods: </strong>Adult patients admitted to psychiatry services and prescribers working in psychiatry or on a general medicine service during the study time frame were invited to participate. Surveys were collected anonymously for both patients and prescribers.</p><p><strong>Results: </strong>NCPM misuse was reported by 38.4% of patients. Trazodone (35%) and quetiapine (30%) were most commonly reported as being misused. Opioid (24.1% vs 4.3%; <i>P</i> = .023) and cannabis use disorders (13.8% vs 0%; <i>P</i> = .019) were reported more frequently in patients who misuse NCPM, whereas no difference was seen for other SUDs (<i>P</i> > .05). There was no difference between psychiatric and general medicine prescribers regarding familiarity with NCPM misuse (n = 21 [87.5%] vs n = 13 [81.3%]; <i>P</i> = .668).</p><p><strong>Discussion: </strong>High rates of NCPM misuse were seen in this patient population. Our findings confirm previous reports of quetiapine misuse and also reveal that trazodone is frequently misused. Based on the observations in this study, the misuse of NCPM is identified as prevalent and noteworthy at our institution, warranting provider education and future studies.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 3","pages":"199-204"},"PeriodicalIF":0.0,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/89/i2168-9709-12-3-199.PMC9190268.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40572088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist impact on medication reconciliation of behavioral health patients boarding in the emergency department.","authors":"Mary Accomando,&nbsp;Kyle DeWitt,&nbsp;Blake Porter","doi":"10.9740/mhc.2022.06.187","DOIUrl":"https://doi.org/10.9740/mhc.2022.06.187","url":null,"abstract":"<p><strong>Introduction: </strong>The high demand for psychiatric services has exceeded the capacity of available resources for behavioral health patients, forcing these patients to seek mental health care in the emergency department. Average lengths of stay for behavioral health boarders commonly extend over multiple days and prior-to-admission (PTA) medication administration may be delayed, which could lead to further deterioration and longer inpatient lengths of stay. Addition of a pharmacist-led medication reconciliation process and pharmacist integration into daily emergency department psychiatry rounds may decrease time to initiation of PTA medications and improve outcomes in this population.</p><p><strong>Methods: </strong>This is a retrospective review of adult patients who required a psychiatric emergency evaluation in a large rural academic medical center emergency department. Objectives were to determine the number and type of medication discrepancies found with pharmacist intervention, and to compare time to initiation of PTA medications with a pharmacist versus a nonpharmacist completing medication reconciliation.</p><p><strong>Results: </strong>A total of 139 patients were identified, 85 patients in August 2019 (no pharmacist [NP]) and 54 in October 2019 (pharmacist involvement [PI]). Among 484 medications reviewed in the PI group, 298 discrepancies were identified. The most common types of discrepancies were no longer taking (n = 99, 33%) and omission (n = 94, 32%). Time to administration of PTA medications was similar between NP and PI groups (median hours, interquartile range: NP: 10.8, 7.8-16.57; PI: 11.49, 6.16-16; <i>P</i> = .179).</p><p><strong>Discussion: </strong>This study depicted one of the many values of pharmacists in the hospital setting, especially in the behavioral health patient population where continuation of accurate PTA medications may prevent further clinical deterioration.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 3","pages":"187-192"},"PeriodicalIF":0.0,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/d9/i2168-9709-12-3-187.PMC9190267.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40570140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic factors related to time to competency for forensic inpatients in a state psychiatric facility.","authors":"Amber Lemons,&nbsp;Courtney A Iuppa,&nbsp;Carrie R Kriz,&nbsp;Lauren A Diefenderfer,&nbsp;Leigh Anne Nelson,&nbsp;Shelby E Lang,&nbsp;Ellie S R Elliott,&nbsp;Joseph Moon,&nbsp;Roger W Sommi","doi":"10.9740/mhc.2022.06.175","DOIUrl":"https://doi.org/10.9740/mhc.2022.06.175","url":null,"abstract":"<p><strong>Introduction: </strong>A defendant who is deemed incompetent to stand trial may go through competency restoration consisting of mental health treatment and legal education. Antipsychotics are often used in treatment; however, there is little data examining their role.</p><p><strong>Methods: </strong>This retrospective study included subjects opined competent to stand trial from July 2016 to February 2020 and prescribed an antipsychotic. The primary outcome was difference in time to competency between antipsychotics. Secondary outcomes included difference in time to competency between groups of antipsychotics, difference in length of stay after opined competent based on medication availability in jail, individual antipsychotics, and formulations.</p><p><strong>Results: </strong>There were 117 subjects included for analysis. There were no differences in time to competency between individual antipsychotics, first- and second-generation antipsychotics, or formulations. Length of stay after opined competent was significantly longer for subjects who were prescribed a long-acting injectable antipsychotic (103 days vs 56 days), who were not able to receive their antipsychotic in jail (104 days vs 54 days), or who were prescribed any formulation of paliperidone compared with olanzapine (88 days vs 35 days).</p><p><strong>Discussion: </strong>Since there were no differences in time to competency, patient-specific factors should be used to choose an agent for competency restoration. Length of stay differences are likely related to the antipsychotic access differences between jails and state psychiatric facilities. Therefore, policies related to antipsychotic access should better align between state psychiatric facilities and jails to improve the capacity of the system and provide better care.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 3","pages":"175-180"},"PeriodicalIF":0.0,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/bd/i2168-9709-12-3-175.PMC9190269.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40572085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating probable nitrofurantoin-induced drug fever from antipsychotic-induced hyperthermia in a patient receiving clozapine.","authors":"Stephen B Vickery,&nbsp;Andrew D Burch,&nbsp;P Brittany Vickery","doi":"10.9740/mhc.2022.06.205","DOIUrl":"https://doi.org/10.9740/mhc.2022.06.205","url":null,"abstract":"<p><p>Nitrofurantoin (NIT) is a commonly utilized antibiotic for the treatment of UTIs. Although well tolerated, NIT is not without potential adverse reactions. This case report details the observation of probable NIT-induced drug fever in a patient receiving clozapine. A 61-year-old female with treatment-refractory schizoaffective disorder was admitted to a psychiatric unit with paranoia and auditory hallucinations, prompting clozapine initiation during day 1 of hospitalization. Due to worsening hallucinations and anxiety, antibiotic therapy with NIT for a presumed UTI was initiated 8 days after admission. Febrile episodes were observed beginning on hospital day (HD) 9, leading to concern for possible neuroleptic malignant syndrome (NMS), which led to clozapine discontinuation. The patient received a total of 3 doses of NIT with continued fever until discontinuation on HD 10. No further complications were encountered, and clozapine was safely resumed on HD 13. Although sparsely described in the medical literature, occurrences of drug fever attributable to NIT are previously reported. A review of the medical literature identified only 5 previously published articles specific to NIT-induced drug fever, none of which specified interruptions of psychotropic therapy for a patient with acute psychiatric decompensation. This case highlights the differential diagnosis of fever related to NIT in a patient receiving clozapine when NMS was initially suspected.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 3","pages":"205-209"},"PeriodicalIF":0.0,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/7e/i2168-9709-12-3-205.PMC9190270.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40572084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxic clozapine level as first indication of severe, acute infection.","authors":"Erica A K Davis,&nbsp;Tyler Hightower,&nbsp;Katherine Ann Cinnamon","doi":"10.9740/mhc.2022.01.045","DOIUrl":"https://doi.org/10.9740/mhc.2022.01.045","url":null,"abstract":"<p><strong>Background: </strong>Clozapine levels can be influenced by many factors, including pharmacogenomic variability, pharmacokinetic drug interactions, and infection/inflammation. The concentration-to-dose ratio (C/D), a measure of a medication's rate of metabolism and clearance, may increase during an acute infection due to decreased medication metabolism and clearance.</p><p><strong>Case report: </strong>A 56-year-old White man was restarted on clozapine and titrated up to 350 mg/d with therapeutic steady-state levels (C/D 1.11) on hospital day (HD) 69. At this time, he was also being treated for COPD exacerbation. For the next month, he continued to complain of cough, but vital signs and chest x-ray remained normal. Labs were unremarkable except for occasional leukocytosis that would resolve on repeat evaluation. A routine clozapine level drawn on HD 104, resulted on day 108 and showed clozapine toxicity with C/D 4.05, although the patient was asymptomatic. After receipt of labs on day 109, showing elevated WBC count, he was immediately sent to the emergency room where he was admitted for treatment of pneumonia. On return to the state hospital, the patient was continued on 100 mg clozapine and titrated to 200 mg/d based on low drug levels. He continued to do well on 200 mg/d clozapine with C/D averaging 1.13 (range, 0.75-1.52).</p><p><strong>Discussion: </strong>Acute infection and illness can lead to significantly increased clozapine levels and toxicity, even if symptoms of toxicity are minimal or absent. This appears to be the first report of a toxic level being the first indication of severe medical illness.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"45-48"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/38/i2168-9709-12-1-45.PMC8788300.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39886728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact on hospital-wide antipsychotic prescribing practices through physician peer comparison letters.","authors":"Erica A K Davis","doi":"10.9740/mhc.2022.01.049","DOIUrl":"https://doi.org/10.9740/mhc.2022.01.049","url":null,"abstract":"<p><p>Peer comparison is a behavioral strategy that provides feedback to individuals on how they compare with others. It is used to improve health care quality, reduce inappropriate prescribing, and improve physician performance. There is very little data on peer comparison and the impact on system-wide prescribing practices, particularly with antipsychotics. To that end, the Maryland statewide pharmacy and therapeutics committee reviews hospital-level antipsychotic data for 5 facilities on a quarterly basis, including high doses and polypharmacy. One facility, Springfield Hospital Center, consistently stood out in 2016 as having higher rates of high doses of haloperidol, olanzapine, and quetiapine as well as patients receiving 3 or more antipsychotics. The pharmacist began to send out individual letters to the psychiatrists detailing their prescribing habits in these areas compared with other psychiatrists and the other state facilities. Over the course of 4 years, the percentage of patients on high doses of 3 antipsychotics substantially decreased. The percentage of patients on polypharmacy in the facility decreased, but not at the same rate as the other hospitals, leaving the facility even higher than the state average at the end of the 4-year period. Pharmacist-initiated physician peer comparison letters were associated with a considerable decrease in the prevalence of high-dose olanzapine, haloperidol, and quetiapine but did not appear to impact antipsychotic polypharmacy. This type of communication may be beneficial for stimulating system-wide changes in prescribing practices for high doses of antipsychotics; however, more individualized interventions are likely needed to reduce antipsychotic polypharmacy.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"49-53"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/8e/i2168-9709-12-1-49.PMC8788299.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39886729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of classroom lectures and a movie recommendation on pharmacy students' attitudes and social distancing toward people with schizophrenia.","authors":"Deborah Oyine Aluh,&nbsp;Kosisochi Chinwendu Amorha,&nbsp;Temitayo Adeola Anthony-Awi","doi":"10.9740/mhc.2022.01.023","DOIUrl":"https://doi.org/10.9740/mhc.2022.01.023","url":null,"abstract":"<p><strong>Introduction: </strong>Stigma and negative attitudes toward people with mental health disorders can impair the provision of pharmaceutical care. The purpose of the study was to assess the effect of classroom lectures on mental health disorders and a movie recommendation on pharmacy students' attitudes and stigma toward persons with schizophrenia (PwS).</p><p><strong>Methods: </strong>The study consisted of a presurvey and postsurvey carried out among final-year pharmacy students of the University of Nigeria Nsukka. A survey comprising 3 sections on sociodemographic details, attitudes toward PwS, and a social distance scale was given to conveniently sampled students before and after lectures on schizophrenia. Students were encouraged to watch a movie about the experiences of a PwS after the first lecture.</p><p><strong>Results: </strong>One hundred seventy-nine students (of the 200 sampled, response rate 91.1%) agreed to participate and completed the survey instrument before the clinical lecture, whereas 108 students who took part in the presurvey participated in the postsurvey (response rate of 76.0%). The overall mean negative attitude score reduced from 2.79 ± 0.412 to 2.72 ± 0.357. The overall mean social distance score increased from 2.48 ± 0.415 to 2.49 ± 0.467, indicating increased stigma. In both presurveys and postsurveys, people with a friend or relative with schizophrenia had a lower mean negative attitude score compared with those who did not. People who had watched the movie recommendation (n = 85) had a higher mean negative attitude (2.74 vs 2.67, <i>P</i> = .433) and a lower social distance toward PwS (2.57 vs 2.48, <i>P</i> = .415).</p><p><strong>Discussion: </strong>Classroom lectures on mental health among pharmacy students might not significantly improve the overall attitudes and social distance toward PwS. Schools of pharmacy should consider alternative formats of teaching mental health-related topics, such as contact with real patients and simulation.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 1","pages":"23-31"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/3f/i2168-9709-12-1-23.PMC8788301.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39886279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}